X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Lead Product(s): Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 2 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Lead Product(s): Ziftomenib
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Kura intends to use the proceeds to fund research and development of its clinical-stage product candidates, other research programs, including KO-539 (ziftomenib), an investigational drug candidate and oral inhibitor of menin-KMT2A for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Ziftomenib
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2024
Details:
The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.
Lead Product(s): Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leukemia & Lymphoma Society
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2023
Details:
The collaboration aims to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Adagrasib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2023
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Tipifarnib, a potent and selective farnesyltransferase inhibitor, is being investigated for the treatment of HRAS mutant head and neck squamous cell carcinoma.
Lead Product(s): Tipifarnib
Therapeutic Area: Oncology Product Name: Zarnestra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The net proceeds will be used to advance company's pipeline of product candidates, including continued development of KO-539 (ziftomenib), a potent and selective small molecule inhibitor of the menin-MLL protein-protein interaction, tipifarnib and KO-2806.
Lead Product(s): Ziftomenib
Therapeutic Area: Oncology Product Name: KO-539
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
